The trademark application TEZSBIRE was filed by Amgen Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on July 12, 2021, and it was registered by office on October 19, 2021 without any oppositions.
The application was filed in English (French was selected as the second language).
Change of name and professional address of the trademark registration was recorded on November 5, 2023.
Goods And Services
The mark was filed in class 5 with Pharmaceutical preparations for the treatment of respiratory diseases and disorders, pulmonary diseases and disorders, cardiovascular diseases and disorders, inflammation, inflammatory diseases and disorders, autoimmune diseases and disorders, cancer, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, neurological diseases and disorders and metabolic diseases and disorders.